BioCentury
ARTICLE | Company News

MOGN gets rights to palonosetron

February 13, 2001 8:00 AM UTC

MGI Pharma entered into a letter of intent with Helsinn Healthcare granting MOGN exclusive North American distribution rights to palonosetron, an intravenous 5-HT3 serotonin receptor antagonist with a...